Sanofi Tells 10th Circ. It Paid $36M To Access EpiPen Market
Sanofi-Aventis US LLC told the Tenth Circuit during oral argument Wednesday that it should not have had to offer a pharmacy benefits manager $36 million in rebates for an unrelated product to be able to compete with Mylan in the market for its emergency allergy treatment EpiPen.